Abstract
Aim: Electronic health records (EHRs) are increasingly used in effectiveness and safety research. However, these studies are often at risk of bias. This study demonstrates the relevance, and discusses challenges, of using target trial emulation to avoid bias, such as selection bias, immortal time bias and confounding when performing observational research with EHRs. Methods: Target trial emulation can be used to identify and address some of the drawbacks of observational research in a systematic way. Potential sources of bias are identified by describing key components of an ideal randomized controlled trial and comparing this to the observational study actually performed. The methods were applied to assess treatment response to antidiabetic treatment using EHRs from patients with diabetes treated in secondary care. Results: Using target trial emulation ensured prevalent users were excluded and patients were not included based on information generally not available when initiating a clinical trial. Furthermore, applying these methods demonstrated how the number of records eligible for use can rapidly decrease. Hereafter, adjustments were performed to address potential sources of bias and it was shown that missing variables essential for adjustment can be an important issue. Conclusions: Using target trial emulation, sources of selection bias and confounding were identified and adjusted for accordingly when analysing treatment response in patients with type 2 diabetes. However, when using EHR data to emulate a target trial, samples containing sufficient information on outcome measures and variables to adjust for confounding and selection bias are essential given the risk of missing data.
| Original language | English |
|---|---|
| Article number | 100545 |
| Journal | Health Policy and Technology |
| Volume | 10 |
| Issue number | 3 |
| DOIs | |
| Publication status | Published - Sept 2021 |
Bibliographical note
Funding Information:Carin Uyl-de Groot reports unrestricted grants from Boehringer Ingelheim, Celgene, Janssen-Cilag, Genzyme, Astellas, Sanofi, Roche, Astra Zeneca, Amgen, Gilead, Merck, Bayer, outside the submitted work. The remaining authors have no competing interest to declare.
Funding Information:
This work was supported by European Union's Horizon 2020 Research and Innovation Programme grant number 644906 . The study sponsor/funder was not involved in the design of the study; the collection, analysis, and interpretation of data; writing the report; and did not impose any restrictions regarding the publication of the report.
Publisher Copyright:
© 2021